<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980885</url>
  </required_header>
  <id_info>
    <org_study_id>AK117-104</org_study_id>
    <nct_id>NCT04980885</nct_id>
  </id_info>
  <brief_title>A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase Ib/II Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open label, phase Ib/II study. All patients are diagnosed with AML, Eastern&#xD;
      Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to&#xD;
      evaluate the safety and efficacy of AK117 + azacitidine in subjects with AML.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite complete remission rate （complete remission + complete remission with incomplete count recovery）</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Number of participants achieving a complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) per European LeukemiaNet (ELN) 2017 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Up to approximately 2 years.</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of CR Without Minimal Residual Disease (CR MRD-)</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>The rate of CR MRD- is the percentage of participants who achieve a CR MRD- as defined by investigators based on ELN 2017 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response (DoCR)</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>The DoCR is measured from the time the assessment criteria are first met for CR (including CR MRD- and CR MRD+/unk) until the first date of AML relapse or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to death or end of study</time_frame>
    <description>The OS is measured from the date of treatment to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-Free Survival (EFS)</measure>
    <time_frame>Up to end of study</time_frame>
    <description>The EFS is defined as time from the date of treatment to the earliest date of documented relapse from complete remission (CR), treatment failure , or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of AK117</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>Serum concentrations of AK117 in individual subjects at different time points after AK117 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies (ADA)</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>Number of subjects with detectable anti-drug antibodies (ADA).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>AK117+Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase Ib: Subjects will receive different doses of A117 in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28 day cycle;&#xD;
Phase II: Subjects will receive AK117 at the recommended Phase 2 dose in combination with azacitidine 75 mg/m2 subcutaneous daily for 7 days of a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK117</intervention_name>
    <description>Subjects receive AK117 intravenously.</description>
    <arm_group_label>AK117+Azacitidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Subjects receive Azacitidine subcutaneously.</description>
    <arm_group_label>AK117+Azacitidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years (at the time consent is obtained).&#xD;
&#xD;
          -  Be able and willing to provide written informed consent and to comply with all&#xD;
             requirements of study participation (including all study procedures).&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3，and 0~2&#xD;
             are required for subjects ≥75 years old.&#xD;
&#xD;
          -  Has a life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Patient with AML diagnosed according to WHO 2016 criteria.&#xD;
&#xD;
          -  Has adequate organ function.&#xD;
&#xD;
          -  All female and male subjects of reproductive potential must agree to use an effective&#xD;
             method of contraception, as determined by the Investigator, during and for 120 days&#xD;
             after the last dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has acute promyelocytic leukemia.&#xD;
&#xD;
          -  Patient has known active central nervous system (CNS) involvement with AML.&#xD;
&#xD;
          -  Favorable risk cytogenetics such as t(8;21), inv(16) or t(16;16) or t(15;17) as per&#xD;
             the National Comprehensive Cancer Network (NCCN) Guidelines Version 2, 2021 for AML.&#xD;
&#xD;
          -  Is currently participating in a study of an investigational agent or using an&#xD;
             investigational device.&#xD;
&#xD;
          -  Has undergone major surgery within 30 days of Study Day 1.&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires systemic treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer.&#xD;
&#xD;
          -  Previous allogeneic hematopoietic stem cell transplant (allo-HSCT) .&#xD;
&#xD;
          -  Prior treatment with any anti-CD47 or anti-SIRPα (signal regulatory protein alpha)&#xD;
             agent.&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in the past 2&#xD;
             years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment.&#xD;
&#xD;
          -  Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the study, interfere with the subject's&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             this subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
          -  Has received a live virus vaccine within 30 days of the planned first dose of study&#xD;
             therapy.&#xD;
&#xD;
          -  Is pregnant, breastfeeding, or expecting to conceive or father a child within the&#xD;
             projected duration of the study including 120 days following the last dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Patient with known allergy or hypersensitivity to AK117, azacitidine or any of their&#xD;
             components.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Weifeng Song, PhD</last_name>
    <phone>+86(0760)89873999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital，Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jin, MD</last_name>
      <phone>0571-87236114</phone>
      <email>jiej0503@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

